A Phase 2 interventional study of Placebo and JNJ-42847922 in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 101 sites in 8 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing seltorexant in Depressive Disorder, Major — 2 open to participants now, 2 under way, 2 of them phase 3. seltorexant · Depressive Disorder, Major.
Among the 12 studies testing seltorexant in Depressive Disorder, Major, this one is the 5th largest by enrollment, is one of 2 that started in 2017, is one of 2 in phase 2, and was the 3rd registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →2 of the 12 studies testing seltorexant in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 4 more countries
Ages 18–74
Janssen Research & Development, LLC · Sites in United States, Argentina, Brazil and 13 more countries
Ages 18–74
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 287 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 176 across the 12 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 2 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
59 studies in Depressive Disorder, Major by Johnson & Johnson: 5 open now, 5 under way, 5 of them phase 3. Of 53 finished, 26 (49%) have results posted.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 18th largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2017, is one of 17 in phase 2, and was the 28th registered.
Johnson & Johnson’s Depressive Disorder, Major studies by the year they started, since 2002.
1 of the studies testing seltorexant in Depressive Disorder, Major that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing seltorexant in Depressive Disorder, Major, from their registry updates:
Among Johnson & Johnson’s 59 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the dose-response relationship of 2 doses of JNJ-42847922 before interim analysis, and potentially 3 doses based on interim analysis results, compared to placebo as adjunctive therapy to an antidepressant drug in improving depressive symptoms in participants with Major Depressive Disorder (MDD) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI); and to assess the safety and tolerability of JNJ-42847922 compared to placebo as adjunctive therapy to an antidepressant in participants with MDD.
The study will investigate the antidepressant effects of a range of doses of JNJ-42847922 (seltorexant) (versus placebo), as adjunctive treatment to antidepressant drugs for treatment of MDD, and will assess the safety and tolerability of JNJ-42847922. The study will be conducted in 3 phases: a screening phase (up to 4 weeks), a double-blind treatment phase (6 weeks), and a post-treatment follow-up phase (2 weeks). Efficacy, safety, pharmacokinetic, and biomarker evaluations will be performed in the study at defined timepoints. The duration of the study will be up to approximately 12 weeks (84 days).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
Drug: Placebo
Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
Drug: JNJ-42847922
Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
Also known as: MIN-202;, Seltorexant
Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.
Time frame: Baseline to Week 6
Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between the initial administration of study drug and 2 days after the last administration of study drug.
Time frame: Up to Week 8
Percentage of Participants With Clinically Significant Laboratory Abnormalities
Percentage of participants with clinically significant laboratory abnormalities were reported which included Gamma-glutamyl transferase (GGT), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Creatine Kinase (CK), Lactate Dehydrogenase (LDH), Albumin , bicarbonate, bilirubin, calcium, chloride, cholesterol, creatinine, direct bilirubin, glucose, high density lipoprotein (HDL) cholesterol, hemoglobin A1C, low density lipoprotein (LDL) cholesterol, phosphate, potassium, protein, sodium, triglycerides, urate, and urea nitrogen.
Time frame: Up to Week 8
Change From Baseline in Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) at Day 8
Change from baseline in vital signs (SBP and DBP) at Day 8 was reported.
Time frame: Baseline and Day 8
Change From Baseline in Vital Signs (SBP and DBP) at Day 22
Change from baseline in vital signs (SBP and DBP) at Day 22 was reported.
Time frame: Baseline and Day 22
Change From Baseline in Vital Signs (SBP and DBP) at Day 42
Change from baseline in vital signs (SBP and DBP) at Day 42 was reported.
Time frame: Baseline and Day 42
Change From Baseline in Vital Signs (SBP and DBP) at Endpoint (Week 6)
Change from baseline in vital signs (SBP and DBP) at endpoint was reported.
Time frame: Baseline and Endpoint (Week 6)
Change From Baseline in Vital Sign (Pulse Rate [PR]) at Day 8
Change from baseline in vital sign (PR) at Day 8 was reported.
Time frame: Baseline and Day 8
Change From Baseline in Vital Sign (PR) at Day 22
Change from baseline in vital sign (PR) at Day 22 was reported.
Time frame: Baseline and Day 22
Change From Baseline in Vital Sign (PR) at Day 42
Change from baseline in vital sign (PR) at Day 42 was reported.
Time frame: Baseline and Day 42
Change From Baseline in Vital Sign (PR) at Endpoint (Week 6)
Change from baseline in vital sign (PR) at endpoint (Week 6) was reported.
Time frame: Baseline and Endpoint (Week 6)
Change From Baseline in Vital Sign (Temperature) at Day 8
Change from baseline in vital Sign (temperature) at Day 8 was reported.
Time frame: Baseline and Day 8
Change From Baseline in Vital Sign (Temperature) at Day 22
Change from baseline in vital Sign (temperature) at Day 22 was reported.
Time frame: Baseline and Day 22
Change From Baseline in Vital Sign (Temperature) at Day 42
Change from baseline in vital Sign (temperature) at Day 42 was reported.
Time frame: Baseline and Day 42
Change From Baseline in Vital Sign (Temperature) at Endpoint (Week 6)
Change from baseline in vital Sign (temperature) at endpoint (Week 6) was reported.
Time frame: Baseline and Endpoint (Week 6)
Change From Baseline in Physical Examination (Waist Circumference) at Day 42
Change from baseline in physical examination (waist circumference) was reported.
Time frame: Baseline and Day 42
Change From Baseline in Physical Examination (Body Weight) at Day 42
Change from baseline in physical examination (body weight) was reported.
Time frame: Baseline and Day 42
Change From Baseline in Physical Examination (Body Mass Index [BMI]) at Day 42
Change from baseline in physical examination (BMI) was reported.
Time frame: Baseline and Day 42
Percentage of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values Outside Pre-defined Limits
Percentage of participants with treatment-emergent abnormal ECG values (Heart rate less than or equal to \[\<=\] 50 or greater than or equal to \[\>=\] 100 beats per minute \[bpm\], PR interval \<=120 or \>=200 milliseconds \[msec\], QRS interval \<=60 or \>=120 msec, and QT interval \<=200 or \>=500 msec) outside pre-defined limits were reported.
Time frame: Up to Week 6
Percentage of Participants With Most Severe Post-baseline Potentially Suicide-Related Category Using Columbia Suicide Severity Rating Scale (C-SSRS)
C-SSRS is a clinician-rated instrument that reports severity of both suicidal ideation and behavior. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior. If no events qualify for score of 1 to 10, score of 0 was assigned (0= "no event that can be assessed on the basis of C-SSRS"). Higher scores indicate greater severity.
Time frame: Up to Week 8
Change From Baseline in Sexual Functioning as Measured by Arizona Sexual Experiences Scale (ASEX) Score at Day 42
Effect on sexual functioning was assessed using the ASEX score. The ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction.
Time frame: Baseline and Day 42
Physician Withdrawal Checklist-20 (PWC-20) Total Score at Day 43
Intensity of discontinuation symptoms was assessed (for example: underlying depression; anxiety-nervousness; dysphoric mood/depression; difficulty concentrating; weakness; fatigue-lethargy-lack of energy; irritability), using the Physician Withdrawal Checklist (PWC-20) administered by a trained clinician/rater. Symptoms are rated on a scale 0 (No symptom present) and 3 (severe symptoms). Total scores range from 0 to 24 calculated by adding the scores of following 8 items: Nausea-Vomiting, Diarrhea, Poor Coordination, Diaphoresis, Tremor-Tremulousness, Dizziness-Lightheadedness, Increased Acuity Sound Smell Touch, Paresthesias. Higher scores indicating more severe symptoms.
Time frame: Day 43
Physician Withdrawal Checklist-20 (PWC-20) Total Score From Day 49 to Day 56
Intensity of discontinuation symptoms was assessed (for example: underlying depression; anxiety-nervousness; dysphoric mood/depression; difficulty concentrating; weakness; fatigue-lethargy-lack of energy; irritability), using the Physician Withdrawal Checklist (PWC-20) administered by a trained clinician/rater. Symptoms are rated on a scale 0 (No symptom present) and 3 (severe symptoms). Total scores range from 0 to 24 calculated by adding the scores of following 8 items: Nausea-Vomiting, Diarrhea, Poor Coordination, Diaphoresis, Tremor-Tremulousness, Dizziness-Lightheadedness, Increased Acuity Sound Smell Touch, Paresthesias. Higher scores indicating more severe symptoms.
Time frame: Day 49 to Day 56
Change From Baseline in the MADRS Total Score by Baseline Insomnia Severity Index (ISI) Score at Day 42
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.
Time frame: Baseline and Day 42
Change From Baseline in ISI Total Score at DB Endpoint (Up to Week 6)
The ISI is a commonly used, 7-item psychometrically validated measure used to rate insomnia. Each item is scored 0 (no problem) to 4 (very big problem) with total between 0-28 which is calculated by adding the scores of all 7 items (absence of insomnia \[0-7\]; sub-threshold insomnia \[8-14\]; moderate insomnia \[15-21\]; and severe insomnia \[22-28\]). The change in ISI total score from baseline at DB endpoint was evaluated. Negative change in score indicates improvement.
Time frame: Baseline and DB Endpoint (Up to Week 6)
Percentage of Participants With Response on Depressive Symptoms Scale Based on MADRS Total Score
Responders are defined as participants with a \>=50 percent (%) improvement in the MADRS total score from baseline to a given timepoint. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Participants with missing values at a given time point were imputed as non-responders.
Time frame: Day 42
Percentage of Participants With Remission of Depressive Symptoms Based on MADRS Total Score
Participants with a MADRS total score of less than or equal to (\<=) 8, \<=10, and \<=12 at a given time point were considered as remitters. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Participants with missing values at a given time point were imputed as non-responders.
Time frame: Day 42
Change From Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Day 42
HAM-A is a 14-item scale designed to measure anxiety in individuals. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. Each of the 14-items in the scale is scored on a 5-point scale, ranging from 0 (a complete lack of that symptom) to 4 (a very severe show of anxiety with that symptom). The total score ranges from 0 to 56 which is calculated by adding the scores of all 14 items, where 0-13 indicates normal range, 14-17 indicates mild severity, 18 -24: mild to moderate severity, 25 -30: moderate to severe, and \>=31: severe. Higher score indicates worsening. Negative change in score indicates improvement.
Time frame: Baseline and Day 42
Percentage of Participants With Response on Anxiety Symptoms Scale Based on HAM-A Total Score
Participants with a \>=50 percent improvement in the HAM-A total score from baseline at a given timepoint were considered as responders. HAM-A is a 14-item scale designed to measure anxiety in individuals. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. Each of the 14-items in the scale is scored on a 5-point scale, ranging from 0 (a complete lack of that symptom) to 4 (a very severe show of anxiety with that symptom). The total score ranges from 0 to 56 which is calculated by adding the scores of all 14 items, where 0-13 indicates normal range, 14-17 indicates mild severity, 18 -24: mild to moderate severity, 25 -30: moderate to severe, and \>=31: severe. Higher score indicates worsening. Participants with missing values at a given time point were imputed as non-responders.
Time frame: Day 42
Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at DB Endpoint (Up to Week 6)
The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S is a 7-point global assessment scale that measures the clinician's impression of the severity of illness exhibited by a participant, rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. Higher scores indicate worsening. Negative change in score indicates improvement.
Time frame: Baseline and DB Endpoint (Up to Week 6)
Change From Baseline in the Sheehan Disability Scale (SDS) Score at Day 42
The SDS is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The scores for the first 3 items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has 1 item on days lost from school or work and 1 item on days when underproductive. Negative change in score indicates improvement.
Time frame: Baseline and Day 42
Change From Baseline in the MADRS Total Score at Day 42 in Participants With Major Depressive Disorder (MDD) With Anxious Distress Versus Participants With MDD Without Anxious Distress
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Negative change in score indicates improvement.
Time frame: Baseline and Day 42
Change From Baseline in Salivary Cortisol Levels, Measured Upon Awakening at Days 8, 22 and 42
Exposure on the hypothalamic-pituitary-adrenal (HPA) axis in participants with MDD was evaluated by assessing change in salivary cortisol levels.
Time frame: Baseline, Days 8, 22 and 42
Plasma Concentrations of Seltorexant and Its Metabolites (M12 and M16)
Plasma concentrations of Seltorexant and its metabolites (M12 and M16) over time were reported.
Time frame: Day 1: Between 0.25 hours (h) to 1.5 hour, 2 to 4 hours, and 6 to 8 hours post-dose; Day 8 (morning): 6 to 12 hours post evening dose of Day 7
Change From Baseline in Depressive Symptoms Using the Patient Health Questionnaire 9-Item (PHQ-9) at DB Endpoint (Up to Week 6)
The PHQ-9 is a 9-item, Patient Reported Outcome (PRO) measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) major depressive disorder (MDD) criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participants item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19) and Severe (20-27).
Time frame: Baseline and DB Endpoint (Up to Week 6)
Change From Baseline in Anhedonia Using the Snaith-Hamilton Pleasure Scale (SHAPS) Score at DB Endpoint (Up to Week 6)
The SHAPS is a 14-item, self-report instrument to assess hedonic capacity in adults with MDD. Each of the items has a set of 4 response categories-Definitely Agree (=1), Agree (=2), Disagree (=3), and Definitely Disagree (=4). A total score is created with either of the Disagree responses receiving a score of 1 and either of the Agree responses receiving a score of 0. The participants item responses are summed to provide a total score ranging from 0 to 14. A higher total SHAPS score indicates higher levels of current anhedonia.
Time frame: Baseline and DB Endpoint (Up to Week 6)
Change From Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form at DB Endpoint (Up to Week 6)
The PROMIS-SD Short Form subscale consists of a static 8 item questionnaire. It assesses the concepts of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items) and worrying about sleep (1 item). Responses to each of the 8 items range from 1 to 5, and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS-SD indicate more of the concept measured (disturbed sleep). Negative change in score indicates improvement.
Time frame: Baseline and DB Endpoint (Up to Week 6)
Change From Baseline in Fatigue Using the Patient Reported Outcome Measurement Information System-Fatigue (PROMIS-F) Short Form Subscale Score at DB Endpoint (Up to Week 6)
The PROMIS-Fatigue Short Form subscale consists of a static 8 item questionnaire. It assesses a range of symptoms from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Ratings are done on a 5-item Likert scale ranging from 0 (not at all) to 5 (very much) or 0 (never) to 5(always) depending upon the question answered. Higher scores on the PROMIS-F indicate more of the concept measured (fatigue). Negative change in score indicates improvement.
Time frame: Baseline and DB Endpoint (Up to Week 6)
Change From Baseline in Severity of Depression Using the Patient Global Impression-Severity (PGI-S) Score at DB Endpoint (Up to Week 6)
The PGI-S is a self-report scale to measure severity of illness (1=none, 2=mild, 3=moderate, 4=severe). Higher score indicates more illness severity. Negative change in score indicates improvement.
Time frame: Baseline and DB Endpoint (Up to Week 6)
Change From Baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) Heath State Index Total Score at DB Endpoint (Up to Week 6)
EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses to 5 EQ-5D-5L dimensions were scored using a utility-weighted algorithm to derive an EQ-5D-5L health status index score between 0 (death) to 100 (full health).
Time frame: Baseline and DB Endpoint (Up to Week 6)
Change From Baseline in EQ-5D-5L Visual Analog Scale (VAS) Total Score at Endpoint (Up to Week 6)
The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and the EQ visual analogue scale (EQ-VAS). EQ-5D-5L (describing and valuing health-related quality of life) descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. Higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement. EQ-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (worst health you can imagine) to 100 (best health you can imagine).
Time frame: Baseline and Endpoint (up to Week 6)
Change From Baseline in Work Productivity and Limitations Using the Work Limitations Questionnaire (WLQ) Short Form Score at DB Endpoint (Up to Week 6)
The WLQ is to assess the on-the-job impact of chronic health problems and/or treatment ("work limitations") in adults. It is a 8-item questionnaire self-report rating scale developed to measure the on-the-job impact of chronic health problems and/or treatment ("work limitations"). It comprises five dimensions of limitations: handling time, physical, mental-interpersonal, productivity loss and output demands. Participants respond to each item with options ranging from 'Almost all of the time' to 'none of the time', or 'Does not apply to my job'. Each dimension of limitations have a scale score ranging from 0 to 100 with lower score indicating low level of work limitations.
Time frame: Baseline and DB Endpoint (Up to Week 6)
| Milestone | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Started | 138 | 33 | 63 | 53 |
| Treated | 137 | 33 | 61 | 52 |
| Completed | 123 | 27 | 55 | 46 |
| Not completed | 15 | 6 | 8 | 7 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 | 0 |
| Withdrew: Protocol violation | 2 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 | 3 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 |
| Withdrew: Received a disallowed concomitant treatment | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 2 | 1 | 1 | 4 |
| Withdrew: Non-compliance with study drug | 2 | 1 | 0 | 1 |
| Withdrew: Other | 4 | 0 | 1 | 0 |
| Milestone | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Started | 138 | 33 | 63 | 53 |
| Completed | 134 | 29 | 57 | 50 |
| Not completed | 4 | 4 | 6 | 3 |
| Withdrew: Other | 4 | 4 | 6 | 3 |
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition.
| score on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score | -12.3 ± 10.95 | -12.2 ± 8.33 | -15.0 ± 12.13 | -14.7 ± 13.29 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between the initial administration of study drug and 2 days after the last administration of study drug.
| percentage of participants | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events as a Measure of Safety and Tolerability | 40.9 | 33.3 | 41.0 | 36.5 |
Percentage of participants with clinically significant laboratory abnormalities were reported which included Gamma-glutamyl transferase (GGT), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP), Creatine Kinase (CK), Lactate Dehydrogenase (LDH), Albumin , bicarbonate, bilirubin, calcium, chloride, cholesterol, creatinine, direct bilirubin, glucose, high density lipoprotein (HDL) cholesterol, hemoglobin A1C, low density lipoprotein (LDL) cholesterol, phosphate, potassium, protein, sodium, triglycerides, urate, and urea nitrogen.
| percentage of participants | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| ALT: Abnormally high | 0 | 0 | 0 | 1.9 |
| Albumin: Abnormally low | 0 | 0 | 0 | 0 |
| Albumin: Abnormally high | 0 | 0 | 0 | 0 |
| ALP: Abnormally high | 0 | 0 | 0 | 0 |
| AST: Abnormally high | 0 | 0 | 0 | 0 |
| Bicarbonate: Abnormally low | 0 | 0 | 0 | 0 |
| Bicarbonate: Abnormally high | 0 | 0 | 0 | 0 |
| Bilirubin: Abnormally high | 0 | 0 | 0 | 0 |
| Calcium: Abnormally low | 0 | 0 | 0 | 0 |
| Calcium: Abnormally high | 0 | 0 | 0 | 0 |
| Chloride: Abnormally low | 0.7 | 0 | 0 | 0 |
| Chloride: Abnormally high | 0 | 0 | 0 | 0 |
| Cholesterol: Abnormally high | 0 | 0 | 0 | 0 |
| CK: Abnormally high | 0 | 0 | 1.7 | 0 |
| Creatinine: Abnormally high | 0 | 0 | 0 | 0 |
| Direct Bilirubin: Abnormally high | 0 | 0 | 0 | 0 |
| GGT: Abnormally high | 0 | 0 | 0 | 0 |
| Glucose: Abnormally low | 0 | 0 | 0 | 0 |
| Glucose: Abnormally high | 0 | 0 | 0 | 0 |
| HDL Cholesterol: Abnormally low | 2.3 | 6.9 | 1.8 | 2.0 |
| Hemoglobin A1C: Abnormally low | 0.0 | 0 | 0 | 0 |
| Hemoglobin A1C: Abnormally high | 0 | 0 | 0 | 0 |
| LDL Cholesterol: Abnormally low | 4.6 | 10.3 | 9.3 | 5.9 |
| LDL Cholesterol: Abnormally high | 7.6 | 6.9 | 1.9 | 11.8 |
| LDH: Abnormally high | 0 | 0 | 0 | 0 |
| Phosphate: Abnormally low | 0.7 | 3.2 | 3.3 | 7.8 |
| Phosphate: Abnormally high | 0 | 0 | 0 | 0 |
| Potassium: Abnormally low | 0 | 0 | 0 | 0 |
| Potassium: Abnormally high | 0.7 | 3.2 | 0 | 0 |
| Protein:Abnormally low | 0 | 0 | 0 | 0 |
| Sodium: Abnormally low | 0 | 0 | 0 | 0 |
| Sodium: Abnormally high | 0 | 0 | 0 | 0 |
| Triglycerides: Abnormally high | 0 | 0 | 0 | 0 |
| Urate: Abnormally low | 0 | 0 | 0 | 0 |
| Urate: Abnormally high | 0 | 0 | 5.0 | 1.9 |
| Urea Nitrogen: Abnormally high | 0 | 0 | 0 | 0 |
Change from baseline in vital signs (SBP and DBP) at Day 8 was reported.
| millimeters of mercury (mmHg) | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Standing DBP | -0.7 ± 6.29 | -0.5 ± 5.22 | 0.7 ± 5.86 | 0.9 ± 6.41 |
| Standing SBP | -0.4 ± 8.16 | -0.8 ± 7.19 | 0.2 ± 8.17 | 0.3 ± 9.71 |
| Supine DBP | -0.8 ± 6.32 | -0.9 ± 6.19 | 2.3 ± 6.14 | 1.2 ± 6.67 |
| Supine SBP | 0.1 ± 8.19 | 1.6 ± 6.56 | 1.5 ± 9.57 | 0.5 ± 10.19 |
Change from baseline in vital signs (SBP and DBP) at Day 22 was reported.
| mmHg | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Standing DBP | 0.0 ± 6.67 | -1.2 ± 5.92 | -0.4 ± 6.90 | 2.4 ± 7.42 |
| Standing SBP | 0.2 ± 7.01 | -1.2 ± 6.55 | -2.7 ± 9.62 | 1.6 ± 11.29 |
| Supine DBP | -0.4 ± 6.81 | -1.8 ± 6.7 | -0.2 ± 7.41 | 2.6 ± 6.81 |
| Supine SBP | 0.8 ± 8.14 | 0.3 ± 4.76 | -0.9 ± 10.78 | 2.2 ± 10.08 |
Change from baseline in vital signs (SBP and DBP) at Day 42 was reported.
| mmHg | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Standing DBP | -0.5 ± 6.22 | 0.3 ± 9.16 | -0.8 ± 6.75 | 2.9 ± 7.96 |
| Standing SBP | -0.5 ± 7.99 | 1.1 ± 7.92 | -3.2 ± 10.57 | 2.0 ± 9.9 |
| Supine DBP | -0.6 ± 7.1 | -1.6 ± 9.23 | 0.0 ± 8.31 | 2.1 ± 7.5 |
| Supine SBP | 0.6 ± 8.88 | -0.5 ± 10.00 | -1.3 ± 10.85 | 1.9 ± 8.35 |
Change from baseline in vital signs (SBP and DBP) at endpoint was reported.
| mmHg | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Standing DBP | -0.3 ± 6.29 | 0.6 ± 8.98 | -0.6 ± 6.78 | 2.8 ± 7.79 |
| Standing SBP | -0.3 ± 8.33 | 1.0 ± 7.42 | -3.1 ± 10.29 | 1.8 ± 9.89 |
| Supine DBP | -0.4 ± 7.08 | -1.4 ± 9.34 | 0.2 ± 8.35 | 2.3 ± 7.39 |
| Supine SBP | 0.6 ± 8.81 | -0.3 ± 9.38 | -1.4 ± 10.52 | 1.6 ± 8.58 |
Change from baseline in vital sign (PR) at Day 8 was reported.
| Beats per minute | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Standing PR | -0.1 ± 7.95 | -0.7 ± 7.07 | 0.9 ± 9.17 | 1.3 ± 9.21 |
| Supine PR | 0 ± 7.15 | -1.2 ± 7.16 | 0.5 ± 6.23 | 1.7 ± 9.32 |
Change from baseline in vital sign (PR) at Day 22 was reported.
| Beats per minute | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Standing PR | 1.4 ± 7.57 | 0.7 ± 7.36 | 1.5 ± 8.27 | 0.3 ± 9.59 |
| Supine PR | 1.5 ± 7.61 | -0.7 ± 7.31 | 2.8 ± 7.94 | 0.9 ± 10.55 |
Change from baseline in vital sign (PR) at Day 42 was reported.
| Beats per minute | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Standing PR | 0.8 ± 7.99 | -1.4 ± 9.35 | 1.5 ± 8.99 | -0.6 ± 9.04 |
| Supine PR | 0.3 ± 8.16 | -2.8 ± 8.67 | 2.4 ± 9.01 | -0.6 ± 9.71 |
Change from baseline in vital sign (PR) at endpoint (Week 6) was reported.
| Beats per minute | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Standing PR | 0.4 ± 8.4 | -1.6 ± 9.27 | 2.1 ± 9.34 | -0.5 ± 9.11 |
| Supine PR | 0.2 ± 8.16 | -2.4 ± 8.97 | 2.4 ± 8.78 | -0.5 ± 9.60 |
Change from baseline in vital Sign (temperature) at Day 8 was reported.
| Celsius | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Vital Sign (Temperature) at Day 8 | -0.01 ± 0.324 | -0.05 ± 0.274 | 0.02 ± 0.278 | 0.06 ± 0.300 |
Change from baseline in vital Sign (temperature) at Day 22 was reported.
| Celsius | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Vital Sign (Temperature) at Day 22 | -0.02 ± 0.299 | -0.01 ± 0.242 | -0.02 ± 0.332 | 0.02 ± 0.392 |
Change from baseline in vital Sign (temperature) at Day 42 was reported.
| Celsius | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Vital Sign (Temperature) at Day 42 | 0.02 ± 0.326 | -0.04 ± 0.291 | -0.05 ± 0.223 | 0.05 ± 0.445 |
Change from baseline in vital Sign (temperature) at endpoint (Week 6) was reported.
| Celsius | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Vital Sign (Temperature) at Endpoint (Week 6) | 0.02 ± 0.317 | -0.03 ± 0.276 | -0.06 ± 0.242 | 0.06 ± 0.437 |
Change from baseline in physical examination (waist circumference) was reported.
| centimeters (cm) | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Physical Examination (Waist Circumference) at Day 42 | 0.31 ± 2.778 | -0.50 ± 1.972 | 0.00 ± 3.523 | -0.48 ± 9.498 |
Change from baseline in physical examination (body weight) was reported.
| Kilograms (kg) | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Physical Examination (Body Weight) at Day 42 | 0.19 ± 2.373 | 0.01 ± 1.889 | 0.05 ± 1.563 | 0.61 ± 1.946 |
Change from baseline in physical examination (BMI) was reported.
| kilograms per meter square (kg/m^2) | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Physical Examination (Body Mass Index [BMI]) at Day 42 | 0.07 ± 0.850 | 0.01 ± 0.662 | 0.02 ± 0.553 | 0.22 ± 0.715 |
Percentage of participants with treatment-emergent abnormal ECG values (Heart rate less than or equal to \[\<=\] 50 or greater than or equal to \[\>=\] 100 beats per minute \[bpm\], PR interval \<=120 or \>=200 milliseconds \[msec\], QRS interval \<=60 or \>=120 msec, and QT interval \<=200 or \>=500 msec) outside pre-defined limits were reported.
| percentage of participants | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Heart rate (<=50) | 0.7 | 0 | 3.4 | 6.0 |
| Heart rate (>=100) | 0.7 | 0 | 1.7 | 0 |
| PR interval (<=120) | 0.7 | 0 | 0 | 0 |
| PR interval (>=200) | 0.7 | 0 | 1.7 | 6.0 |
| QRS interval (<=60) | 0 | 0 | 0 | 0 |
| QRS interval (>=120) | 0 | 3.3 | 0 | 0 |
| QT interval (<=200) | 0 | 0 | 0 | 0 |
| QT interval (>=500) | 0 | 3.3 | 0 | 0 |
C-SSRS is a clinician-rated instrument that reports severity of both suicidal ideation and behavior. Suicidal ideation was classified on a 5-item scale: 1 (wish to be dead), 2 (nonspecific active suicidal thoughts), 3 (active suicidal ideation with any methods \[not plan\] without intent to act), 4 (active suicidal ideation with some intent to act, without specific plan), and 5 (active suicidal ideation with specific plan and intent). Suicidal behavior is classified on a 5-item scale: 0 (no suicidal behavior), 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), and 4 (actual attempt). More than 1 classification can be selected provided they represent separate episodes. Minimum total score 0, maximum total score 5; higher total scores indicate more suicidal ideation and/or suicidal behavior. If no events qualify for score of 1 to 10, score of 0 was assigned (0= "no event that can be assessed on the basis of C-SSRS"). Higher scores indicate greater severity.
| percentage of participants | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| No Event | 94.9 | 96.9 | 96.7 | 94.1 |
| Suicidal ideation | 5.1 | 3.1 | 3.3 | 5.9 |
| Suicidal behavior | 0 | 0 | 0 | 0 |
Effect on sexual functioning was assessed using the ASEX score. The ASEX is a five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Each of the 5 items is rated on a 6-point scale, ranging from 1 to 6. The 5 items are summed to create a total score, ranging from 5 to 30, with the higher scores indicating more sexual dysfunction.
| score on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Sexual Functioning as Measured by Arizona Sexual Experiences Scale (ASEX) Score at Day 42 | -1.4 ± 4.55 | -2.2 ± 3.62 | -2.4 ± 4.55 | -2.5 ± 4.94 |
Intensity of discontinuation symptoms was assessed (for example: underlying depression; anxiety-nervousness; dysphoric mood/depression; difficulty concentrating; weakness; fatigue-lethargy-lack of energy; irritability), using the Physician Withdrawal Checklist (PWC-20) administered by a trained clinician/rater. Symptoms are rated on a scale 0 (No symptom present) and 3 (severe symptoms). Total scores range from 0 to 24 calculated by adding the scores of following 8 items: Nausea-Vomiting, Diarrhea, Poor Coordination, Diaphoresis, Tremor-Tremulousness, Dizziness-Lightheadedness, Increased Acuity Sound Smell Touch, Paresthesias. Higher scores indicating more severe symptoms.
| score on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Physician Withdrawal Checklist-20 (PWC-20) Total Score at Day 43 | 0.9 ± 1.68 | 0.2 ± 0.6 | 0.7 ± 1.6 | 0.5 ± 0.87 |
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. The ISI has 7 questions, each rated on a 5-point Likert scale ranging from 0 to 4. The total score is calculated as the sum of the 7 items ranging from 0 to 28. Higher scores represent a more severe condition.
| score on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Day 42: Baseline ISI score per IWRS less than (<)15 | -13.3 ± 10.83 | -12.6 ± 8.01 | -13.0 ± 11.38 | -14.9 ± 12.14 |
| Day 42: Baseline ISI score per IWRS>=15 | -11.6 ± 11.06 | -10.4 ± 10.41 | -16.5 ± 12.62 | -14.6 ± 13.87 |
The ISI is a commonly used, 7-item psychometrically validated measure used to rate insomnia. Each item is scored 0 (no problem) to 4 (very big problem) with total between 0-28 which is calculated by adding the scores of all 7 items (absence of insomnia \[0-7\]; sub-threshold insomnia \[8-14\]; moderate insomnia \[15-21\]; and severe insomnia \[22-28\]). The change in ISI total score from baseline at DB endpoint was evaluated. Negative change in score indicates improvement.
| Units on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in ISI Total Score at DB Endpoint (Up to Week 6) | -6.3 ± 6.73 | -4.9 ± 6.22 | -8.7 ± 6.91 | -8.5 ± 8.73 |
Responders are defined as participants with a \>=50 percent (%) improvement in the MADRS total score from baseline to a given timepoint. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Participants with missing values at a given time point were imputed as non-responders.
| Percentage of participants | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Percentage of Participants With Response on Depressive Symptoms Scale Based on MADRS Total Score | 28.5 | 24.2 | 41.0 | 38.5 |
Participants with a MADRS total score of less than or equal to (\<=) 8, \<=10, and \<=12 at a given time point were considered as remitters. MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Participants with missing values at a given time point were imputed as non-responders.
| Percentage of participants | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| MADRS (<=12) | 19.0 | 15.2 | 29.5 | 26.9 |
| MADRS (<=10) | 17.5 | 9.1 | 26.2 | 26.9 |
| MADRS (<=8) | 16.1 | 6.1 | 23.0 | 19.2 |
HAM-A is a 14-item scale designed to measure anxiety in individuals. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. Each of the 14-items in the scale is scored on a 5-point scale, ranging from 0 (a complete lack of that symptom) to 4 (a very severe show of anxiety with that symptom). The total score ranges from 0 to 56 which is calculated by adding the scores of all 14 items, where 0-13 indicates normal range, 14-17 indicates mild severity, 18 -24: mild to moderate severity, 25 -30: moderate to severe, and \>=31: severe. Higher score indicates worsening. Negative change in score indicates improvement.
| Units on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (HAM-A) Total Score at Day 42 | -8.7 ± 7.92 | -9.9 ± 5.57 | -9.6 ± 9.31 | -9.9 ± 10.17 |
Participants with a \>=50 percent improvement in the HAM-A total score from baseline at a given timepoint were considered as responders. HAM-A is a 14-item scale designed to measure anxiety in individuals. Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented. Each of the 14-items in the scale is scored on a 5-point scale, ranging from 0 (a complete lack of that symptom) to 4 (a very severe show of anxiety with that symptom). The total score ranges from 0 to 56 which is calculated by adding the scores of all 14 items, where 0-13 indicates normal range, 14-17 indicates mild severity, 18 -24: mild to moderate severity, 25 -30: moderate to severe, and \>=31: severe. Higher score indicates worsening. Participants with missing values at a given time point were imputed as non-responders.
| Percentage of participants | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Percentage of Participants With Response on Anxiety Symptoms Scale Based on HAM-A Total Score | 37.2 | 57.6 | 50.8 | 46.2 |
The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S is a 7-point global assessment scale that measures the clinician's impression of the severity of illness exhibited by a participant, rating according to: 1=normal (not at all ill); 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill participants. Higher scores indicate worsening. Negative change in score indicates improvement.
| Units on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at DB Endpoint (Up to Week 6) | -1.0 (-5 to 2) | -1.0 (-3 to 1) | -1.0 (-5 to 1) | -1.0 (-5 to 1) |
The SDS is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The scores for the first 3 items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has 1 item on days lost from school or work and 1 item on days when underproductive. Negative change in score indicates improvement.
| Units on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in the Sheehan Disability Scale (SDS) Score at Day 42 | -7.9 ± 6.99 | -7.5 ± 5.19 | -7.9 ± 7.46 | -5.9 ± 9.20 |
MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score range of 0-60 which is calculated by adding the scores of all 10 items. Higher scores represent a more severe condition. Negative change in score indicates improvement.
| Units on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| MDD with Anxious Distress | -13.9 ± 11.50 | -11.0 ± 8.67 | -16.9 ± 12.31 | -15.3 ± 13.0 |
| MDD without Anxious distress | -9.7 ± 9.59 | -13.4 ± 8.15 | -12.5 ± 11.70 | -13.8 ± 14.63 |
Exposure on the hypothalamic-pituitary-adrenal (HPA) axis in participants with MDD was evaluated by assessing change in salivary cortisol levels.
| nanomoles per Liter (nmol/L) | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change at Day 8 | 0.2 ± 8.41 | 0.7 ± 7.24 | 0.0 ± 8.64 | -0.4 ± 6.19 |
| Change at Day 22 | 0.4 ± 8.65 | 2.1 ± 6.39 | 0.7 ± 6.75 | 1.0 ± 10.75 |
| Change at Day 42 | 1.0 ± 10.85 | 1.5 ± 6.15 | -1.2 ± 6.67 | -0.5 ± 6.69 |
Plasma concentrations of Seltorexant and its metabolites (M12 and M16) over time were reported.
| nanograms per milliliter (ng/mL) | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|
| Seltorexant: Day 1, 0.25h-1.5h | 181 ± 165 | 277 ± 291 | 535 ± 500 |
| Seltorexant: Day 1, 2-4h | 199 ± 113 | 374 ± 232 | 647 ± 325 |
| Seltorexant: Day 1, 6-8h | 117 ± 99.3 | 167 ± 179 | 207 ± 169 |
| Seltorexant: Day 8, Morning (6 to 12 hours post evening dose of Day 7) | 52.8 ± 65.8 | 69.4 ± 119 | 104 ± 203 |
| M12: Day 1,0.25h-1.5h | 118 ± 107 | 194 ± 223 | 357 ± 367 |
| M12: Day 1, 2-4h | 146 ± 58.8 | 283 ± 185 | 513 ± 284 |
| M12: Day 1, 6-8h | 105 ± 73.5 | 187 ± 189 | 279 ± 278 |
| M12: Day 8, Morning (6 to 12 hours post evening dose of Day 7) | 76.2 ± 79 | 99 ± 133 | 169 ± 251 |
| M16: Day 1, 0.25h-1.5h | 29.1 ± 30.2 | 47 ± 53.4 | 71.4 ± 78.3 |
| M16: Day 1, 2-4h | 33.3 ± 15.7 | 61.4 ± 35.7 | 101 ± 49.3 |
| M16: Day 1, 6-8h | 27.5 ± 16.6 | 40.1 ± 31.4 | 70.6 ± 33.6 |
| M16: Day 8, Morning (6 to 12 hours post evening dose of Day 7) | 23.7 ± 14.9 | 37.6 ± 36.1 | 61.7 ± 43.7 |
The PHQ-9 is a 9-item, Patient Reported Outcome (PRO) measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders-5th Edition (DSM-5) major depressive disorder (MDD) criteria. Each item is rated on a 4 point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participants item responses are summed to provide a total score (range of 0 to 27), with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19) and Severe (20-27).
| Units on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Depressive Symptoms Using the Patient Health Questionnaire 9-Item (PHQ-9) at DB Endpoint (Up to Week 6) | -7.3 ± 6.14 | -6.2 ± 5.48 | -8.6 ± 6.66 | -7.0 ± 7.64 |
The SHAPS is a 14-item, self-report instrument to assess hedonic capacity in adults with MDD. Each of the items has a set of 4 response categories-Definitely Agree (=1), Agree (=2), Disagree (=3), and Definitely Disagree (=4). A total score is created with either of the Disagree responses receiving a score of 1 and either of the Agree responses receiving a score of 0. The participants item responses are summed to provide a total score ranging from 0 to 14. A higher total SHAPS score indicates higher levels of current anhedonia.
| Units on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Anhedonia Using the Snaith-Hamilton Pleasure Scale (SHAPS) Score at DB Endpoint (Up to Week 6) | -3.6 ± 4.44 | -2.3 ± 4.09 | -4.2 ± 4.50 | -3.2 ± 5.20 |
The PROMIS-SD Short Form subscale consists of a static 8 item questionnaire. It assesses the concepts of sleep initiation (2 items), quality of sleep (3 items), early morning feelings (2 items) and worrying about sleep (1 item). Responses to each of the 8 items range from 1 to 5, and the range of possible summed raw scores is 8 to 40. Higher scores on the PROMIS-SD indicate more of the concept measured (disturbed sleep). Negative change in score indicates improvement.
| Units on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Sleep Disturbance Using the Patient Reported Outcome Measurement Information System-Sleep Disturbance (PROMIS-SD) Short Form at DB Endpoint (Up to Week 6) | -6.4 ± 8.53 | -5.1 ± 8.39 | -10.2 ± 9.21 | -10.9 ± 9.25 |
The PROMIS-Fatigue Short Form subscale consists of a static 8 item questionnaire. It assesses a range of symptoms from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Ratings are done on a 5-item Likert scale ranging from 0 (not at all) to 5 (very much) or 0 (never) to 5(always) depending upon the question answered. Higher scores on the PROMIS-F indicate more of the concept measured (fatigue). Negative change in score indicates improvement.
| Units on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Fatigue Using the Patient Reported Outcome Measurement Information System-Fatigue (PROMIS-F) Short Form Subscale Score at DB Endpoint (Up to Week 6) | -7.7 ± 8.45 | -7.4 ± 8.25 | -9.4 ± 8.62 | -8.0 ± 10.29 |
The PGI-S is a self-report scale to measure severity of illness (1=none, 2=mild, 3=moderate, 4=severe). Higher score indicates more illness severity. Negative change in score indicates improvement.
| Units on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in Severity of Depression Using the Patient Global Impression-Severity (PGI-S) Score at DB Endpoint (Up to Week 6) | -1.0 (-3 to 2) | 0.0 (-2 to 1) | -1.0 (-3 to 1) | -1.0 (-3 to 1) |
EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). The responses to 5 EQ-5D-5L dimensions were scored using a utility-weighted algorithm to derive an EQ-5D-5L health status index score between 0 (death) to 100 (full health).
| Units on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) Heath State Index Total Score at DB Endpoint (Up to Week 6) | 0.188 ± 0.2201 | 0.143 ± 0.1856 | 0.229 ± 0.2084 | 0.158 ± 0.2841 |
The EQ-5D-5L is a standardized instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It consists of the EQ-5D-5L descriptive system and the EQ visual analogue scale (EQ-VAS). EQ-5D-5L (describing and valuing health-related quality of life) descriptive system comprises 5 dimensions of health (mobility, self -care, usual activities, pain/discomfort, and anxiety/depression) to describe the participant's current health state. Each dimension comprises 5 levels with corresponding numeric scores, where 1 indicates no problems, and 5 indicates extreme problems. Higher scores representing a better health state. An increase in the EQ-5D-5L total score indicates improvement. EQ-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on scale of 0 (worst health you can imagine) to 100 (best health you can imagine).
| Units on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Change From Baseline in EQ-5D-5L Visual Analog Scale (VAS) Total Score at Endpoint (Up to Week 6) | 17.4 ± 20.55 | 8.9 ± 19.34 | 23.4 ± 21.18 | 20.1 ± 23.08 |
The WLQ is to assess the on-the-job impact of chronic health problems and/or treatment ("work limitations") in adults. It is a 8-item questionnaire self-report rating scale developed to measure the on-the-job impact of chronic health problems and/or treatment ("work limitations"). It comprises five dimensions of limitations: handling time, physical, mental-interpersonal, productivity loss and output demands. Participants respond to each item with options ranging from 'Almost all of the time' to 'none of the time', or 'Does not apply to my job'. Each dimension of limitations have a scale score ranging from 0 to 100 with lower score indicating low level of work limitations.
| Units on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Time management | -21.3 ± 30.41 | -18.2 ± 28.28 | -21.8 ± 34.46 | -20.8 ± 37.48 |
| Physical demands | -15.2 ± 23.64 | -23.5 ± 26.10 | -11.7 ± 31.4 | -14.3 ± 35.37 |
| Mental interpersonal scale | -21.2 ± 27.61 | -19.5 ± 25.28 | -26.28 ± 27.89 | -15.9 ± 31.76 |
| Output demand scale | -23.9 ± 26.72 | -22.2 ± 27.8 | -20.3 ± 30.08 | -21.7 ± 35.80 |
| Productivity loss | -5.1 ± 5.56 | -4.7 ± 5.30 | -4.7 ± 6.16 | -4.6 ± 7.02 |
Intensity of discontinuation symptoms was assessed (for example: underlying depression; anxiety-nervousness; dysphoric mood/depression; difficulty concentrating; weakness; fatigue-lethargy-lack of energy; irritability), using the Physician Withdrawal Checklist (PWC-20) administered by a trained clinician/rater. Symptoms are rated on a scale 0 (No symptom present) and 3 (severe symptoms). Total scores range from 0 to 24 calculated by adding the scores of following 8 items: Nausea-Vomiting, Diarrhea, Poor Coordination, Diaphoresis, Tremor-Tremulousness, Dizziness-Lightheadedness, Increased Acuity Sound Smell Touch, Paresthesias. Higher scores indicating more severe symptoms.
| score on a scale | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg |
|---|---|---|---|---|
| Physician Withdrawal Checklist-20 (PWC-20) Total Score From Day 49 to Day 56 | 0.9 ± 1.91 | 0.4 ± 0.78 | 0.8 ± 1.64 | 0.7 ± 1.25 |
Collected over Up to Week 8. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/137 (0%) | 1/137 (0.7%) | 22/137 (16.1%) |
| Double-blind: Seltorexant 10 mg | 0/33 (0%) | 0/33 (0%) | 5/33 (15.2%) |
| Double-blind: Seltorexant 20 mg | 0/61 (0%) | 0/61 (0%) | 11/61 (18%) |
| DB: Seltorexant 40 mg | 0/52 (0%) | 0/52 (0%) | 12/52 (23.1%) |
| Follow-up: Placebo | 0/137 (0%) | 0/137 (0%) | 1/137 (0.7%) |
| Follow-up: Seltorexant 10 mg | 0/33 (0%) | 0/33 (0%) | 0/33 (0%) |
| Follow-up: Seltorexant 20 mg | 0/61 (0%) | 0/61 (0%) | 0/61 (0%) |
| Follow-up: Seltorexant 40 mg | 0/52 (0%) | 0/52 (0%) | 1/52 (1.9%) |
| Event | Placebo | Double-blind: Seltorexant 10 mg | Double-blind: Seltorexant 20 mg | DB: Seltorexant 40 mg | Follow-up: Placebo | Follow-up: Seltorexant 10 mg | Follow-up: Seltorexant 20 mg | Follow-up: Seltorexant 40 mg |
|---|---|---|---|---|---|---|---|---|
| Polycythaemia VeraNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/137 | 0/33 | 0/61 | 0/52 | 0/137 | 0/33 | 0/61 | 0/52 |
| Event | Placebo | Double-blind: Seltorexant 10 mg | Double-blind: Seltorexant 20 mg | DB: Seltorexant 40 mg | Follow-up: Placebo | Follow-up: Seltorexant 10 mg | Follow-up: Seltorexant 20 mg | Follow-up: Seltorexant 40 mg |
|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 9/137 | 2/33 | 1/61 | 6/52 | 0/137 | 0/33 | 0/61 | 0/52 |
| SomnolenceNervous system disorders | 7/137 | 1/33 | 6/61 | 2/52 | 0/137 | 0/33 | 0/61 | 0/52 |
| NauseaGastrointestinal disorders | 4/137 | 1/33 | 4/61 | 3/52 | 1/137 | 0/33 | 0/61 | 0/52 |
| InsomniaPsychiatric disorders | 1/137 | 2/33 | 1/61 | 2/52 | 0/137 | 0/33 | 0/61 | 1/52 |
| DiarrhoeaGastrointestinal disorders | 7/137 | 0/33 | 0/61 | 1/52 | 0/137 | 0/33 | 0/61 | 0/52 |
Full analysis set included all participants who were randomly assigned to study drug and received at least 1 dose of study drug.
| Age, Continuous(years) | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg | Total |
|---|---|---|---|---|---|
| Mean | 49.6 ± 11.71 | 49.4 ± 15.31 | 48.5 ± 13.56 | 48.3 ± 10.52 | 49.1 ± 12.34 |
| Age, Customized(Participants) | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg | Total |
|---|---|---|---|---|---|
| Adults (18-64 years) | 131 | 29 | 59 | 51 | 270 |
| From 65 to 84 years | 6 | 4 | 2 | 1 | 13 |
| 85 years and over | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg | Total |
|---|---|---|---|---|---|
| Female | 74 | 20 | 30 | 28 | 152 |
| Male | 63 | 13 | 31 | 24 | 131 |
| Race/Ethnicity, Customized(Participants) | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg | Total |
|---|---|---|---|---|---|
| Asian | 20 | 3 | 9 | 8 | 40 |
| Black or African American | 11 | 1 | 2 | 5 | 19 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| White | 105 | 29 | 50 | 39 | 223 |
| Race/Ethnicity, Customized(Participants) | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 15 | 1 | 5 | 7 | 28 |
| Not Hispanic or Latino | 120 | 31 | 53 | 42 | 246 |
| Unknown or Not Reported | 2 | 1 | 3 | 3 | 9 |
| Region of Enrollment(Participants) | Placebo | Seltorexant 10 mg | Seltorexant 20 mg | Seltorexant 40 mg | Total |
|---|---|---|---|---|---|
| BULGARIA | 35 | 2 | 17 | 12 | 66 |
| FINLAND | 3 | 1 | 1 | 5 | 10 |
| GERMANY | 0 | 1 | 1 | 1 | 3 |
| JAPAN | 18 | 3 | 8 | 8 | 37 |
| RUSSIAN FEDERATION | 18 | 16 | 8 | 3 | 45 |
| UKRAINE | 22 | 6 | 6 | 5 | 39 |
| UNITED STATES | 41 | 4 | 20 | 18 | 83 |
Showing the first 100 of 101 sites across 8 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2017 to primary completion in Jan 2019, 16 months.
Results were first posted in Feb 2022, 3 years after primary completion. A results delay was requested in Jan 2020.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 16 months is close to that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Seltorexant
Janssen Research & Development, LLC →